Nothing Special   »   [go: up one dir, main page]

Dragulescu-Andrasi et al., 2006 - Google Patents

Cell-permeable peptide nucleic acid designed to bind to the 5 '-untranslated region of E-cadherin transcript induces potent and sequence-specific antisense effects

Dragulescu-Andrasi et al., 2006

View PDF
Document ID
2752067758014173225
Author
Dragulescu-Andrasi A
Rapireddy S
He G
Bhattacharya B
Hyldig-Nielsen J
Zon G
Ly D
Publication year
Publication venue
Journal of the American Chemical Society

External Links

Snippet

Establishing a general and effective method for regulating gene expression in mammalian systems is important for many aspects of biological and biomedical research. Herein we report the antisense activities of a cell-permeable, guanidine-based peptide nucleic acid …
Continue reading at www.chem.cmu.edu (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Similar Documents

Publication Publication Date Title
Dragulescu-Andrasi et al. Cell-permeable peptide nucleic acid designed to bind to the 5 ‘-untranslated region of E-cadherin transcript induces potent and sequence-specific antisense effects
Zhou et al. Novel binding and efficient cellular uptake of guanidine-based peptide nucleic acids (GPNA)
Hu et al. Inhibiting gene expression with peptide nucleic acid (PNA)− peptide conjugates that target chromosomal DNA
Doyle et al. Inhibition of gene expression inside cells by peptide nucleic acids: effect of mRNA target sequence, mismatched bases, and PNA length
JP6422463B2 (en) Natural antisense and non-coding RNA transcripts as drug targets
Lusic et al. Photochemical DNA activation
Gebski et al. Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle
Schmajuk et al. Antisense oligonucleotides with different backbones: modification of splicing pathways and efficacy of uptake
Gasparello et al. Efficient cell penetration and delivery of peptide nucleic acids by an argininocalix [4] arene
Sazani et al. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs
Kaihatsu et al. Intracellular uptake and inhibition of gene expression by PNAs and PNA− peptide conjugates
Lehto et al. Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells
Karras et al. Peptide nucleic acids are potent modulators of endogenous pre-mRNA splicing of the murine interleukin-5 receptor-α chain
Gagnon et al. Antisense and antigene inhibition of gene expression by cell-permeable oligonucleotide–oligospermine conjugates
Gupta et al. Recognition of double-stranded RNA by guanidine-modified peptide nucleic acids
Cogoi et al. G-rich oligonucleotide inhibits the binding of a nuclear protein to the Ki-ras promoter and strongly reduces cell growth in human carcinoma pancreatic cells
Moccia et al. Insights on chiral, backbone modified peptide nucleic acids: properties and biological activity
Puah et al. Selective binding to mRNA duplex regions by chemically modified peptide nucleic acids stimulates ribosomal frameshifting
Martin et al. A single amino acid substitution in ORF1 dramatically decreases L1 retrotransposition and provides insight into nucleic acid chaperone activity
Beane et al. Inhibiting gene expression with locked nucleic acids (LNAs) that target chromosomal DNA
De Serres-Bérard et al. Recent progress and challenges in the development of antisense therapies for myotonic dystrophy type 1
Rapozzi et al. Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids
Endoh et al. Triple-Helical Binding of Peptide Nucleic Acid Inhibits Maturation of Endogenous MicroRNA-197
Liu et al. Efficient and isoform-selective inhibition of cellular gene expression by peptide nucleic acids
McIntosh et al. Polyglutamine ataxias: our current molecular understanding and what the future holds for antisense therapies